---
title: "ArriVent Retains Buy Rating as Analyst Sees Upside from Broader Pipeline Despite Trial Miss, Cutting Price Target to $22"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301071044.md"
description: "JonesTrading analyst Boris Peaker maintained a Buy rating on ArriVent BioPharma but lowered the price target to $22 from $45. Despite a Phase III trial miss in NSCLC, Peaker cites strong chemotherapy controls and comparable PFS for firmonertinib as reasons to retain the positive outlook. He highlights upside potential from the broader pipeline, including the ALPACCA study and ADC program, projecting peak sales of $1.3 billion. LifeSci Capital also issued a Buy rating with a $15 target."
datetime: "2026-10-06T19:55:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301071044.md)
  - [en](https://longbridge.com/en/news/301071044.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301071044.md)
generator: "portal-rs"
---

# ArriVent Retains Buy Rating as Analyst Sees Upside from Broader Pipeline Despite Trial Miss, Cutting Price Target to $22

Analyst Boris Peaker from JonesTrading reiterated a Buy rating on ArriVent BioPharma, Inc. and decreased the price target to $22.00 from $45.00.

Boris Peaker has given his Buy rating due to a combination of factors, even though the recent Phase III trial in first-line EGFR ex20 mutant NSCLC did not meet its primary endpoint. He notes that the chemotherapy control group performed unusually well versus historical expectations, while firmonertinib’s progression-free survival aligned with prior projections and remained comparable to other targeted therapies in the class.

Peaker also emphasizes that ArriVent’s broader pipeline, including the ongoing ALPACCA Phase III monotherapy study and its antibody-drug conjugate program, continues to offer meaningful upside potential. After removing the failed indication and lowering probability of success in another setting, he still projects peak sales around $1.3 billion and, with a reduced price target of $22, sees the current valuation as attractive enough to support a Buy recommendation. 

In another report released today, LifeSci Capital also maintained a Buy rating on the stock with a $15.00 price target.

### Related Stocks

- [AVBP.US](https://longbridge.com/en/quote/AVBP.US.md)

## Related News & Research

- [ArriVent doses first patient in Phase 1 trial of ARR-002 dual-target ADC for ovarian, endometrial cancer](https://longbridge.com/en/news/301620875.md)
- [ArriVent says Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion NSCLC misses primary PFS endpoint](https://longbridge.com/en/news/301032671.md)
- [ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low](https://longbridge.com/en/news/301066580.md)
- [ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)](https://longbridge.com/en/news/301079950.md)
- [TSMC Q3 Earnings Preview: Can Profit Hit a Record High for a Sixth Straight Quarter? Wall Street's Highest Target Price Is $665](https://longbridge.com/en/news/301683133.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**